Dr. Uma Borate, MD
Claim this profileOhio State University Comprehensive Cancer Center
Studies Acute Myeloid Leukemia
Studies Myelodysplastic Syndrome
16 reported clinical trials
30 drugs studied
About Uma Borate, MD
Education:
- Obtained MD from Ohio State University College of Medicine in 2015.
- Completed Residency in Internal Medicine at The Ohio State University Wexner Medical Center in 2018.
- Finished Fellowship in Hematology and Oncology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in 2021.
Experience:
- Specializes in Internal Medicine, Hematology, and Oncology.
- Trained at The Ohio State University Comprehensive Cancer Center.
Area of expertise
1Acute Myeloid Leukemia
hydroxyurea
azacitidine
decitabine
2Myelodysplastic Syndrome
RARA positive
Affiliated Hospitals
Clinical Trials Uma Borate, MD is currently running
Epoetin Alfa vs Luspatercept
for Myelodysplastic Syndrome
This trial is testing two treatments, Luspatercept and epoetin alfa, to see which is better for treating anemia in adults with certain types of myelodysplastic syndromes (MDS). The participants have not used similar treatments before and do not need regular blood transfusions. Luspatercept helps red blood cells mature, while epoetin alfa increases their production.
Recruiting2 awards Phase 3
Venetoclax + Azacitidine
for Myelodysplastic Syndrome
This phase II trial studies the effect of venetoclax and azacitidine in treating patients with therapy related or secondary myelodysplastic syndrome. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax in combination with azacitidine may work better in treating patients with therapy related or secondary myelodysplastic syndrome.
Recruiting1 award Phase 2
More about Uma Borate, MD
Clinical Trial Related3 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Uma Borate, MD has experience with
- Azacitidine
- Venetoclax
- Canakinumab
- Luspatercept
- SNDX-5613
- Gilteritinib
Breakdown of trials Uma Borate, MD has run
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloid Leukemia
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Uma Borate, MD specialize in?
Uma Borate, MD focuses on Acute Myeloid Leukemia and Myelodysplastic Syndrome. In particular, much of their work with Acute Myeloid Leukemia has involved hydroxyurea patients, or patients who are azacitidine.
Is Uma Borate, MD currently recruiting for clinical trials?
Yes, Uma Borate, MD is currently recruiting for 11 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Uma Borate, MD has studied deeply?
Yes, Uma Borate, MD has studied treatments such as Azacitidine, Venetoclax, Canakinumab.
What is the best way to schedule an appointment with Uma Borate, MD?
Apply for one of the trials that Uma Borate, MD is conducting.
What is the office address of Uma Borate, MD?
The office of Uma Borate, MD is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.